The KRAS pathway was considered "undruggable". Read how Revvity's preclinical services helped Boehringer Ingelheim generate compounds to target this pathway.
In this literature review you will learn:
For research use only. Not for use in diagnostic procedures.
The impact of pan-KRAS inhibitors on cancer drug discovery